相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial.
Domenica Lorusso et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
N. Colombo et al.
ANNALS OF ONCOLOGY (2019)
Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial.
Michael Friedlander et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
When and how to use data from randomised trials to develop or validate prognostic models
Romin Pajouheshnia et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy
Chee Khoon Lee et al.
EUROPEAN JOURNAL OF CANCER (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
Michael Friedlander et al.
BRITISH JOURNAL OF CANCER (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits
L. J. Fallowfield et al.
SUPPORTIVE CARE IN CANCER (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
Stephanie Lheureux et al.
CLINICAL CANCER RESEARCH (2017)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer
C. K. Lee et al.
ANNALS OF ONCOLOGY (2013)
The Median Informs the Message: Accuracy of Individualized Scenarios for Survival Time Based on Oncologists' Estimates
Belinda E. Kiely et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer
David M. Hyman et al.
CANCER (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Rohini Roy et al.
NATURE REVIEWS CANCER (2012)
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer
C. K. Lee et al.
BRITISH JOURNAL OF CANCER (2011)
Clinical Trials in Recurrent Ovarian Cancer
Michael Friedlander et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2011)
Association of BRCA1 and BRCA2 Mutations With Survival, Chemotherapy Sensitivity, and Gene Mutator Phenotype in Patients With Ovarian Cancer
Da Yang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
Barbara Norquist et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Molecular predictive and prognostic markers in non-small-cell lung cancer
Linda E. Coate et al.
LANCET ONCOLOGY (2009)
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards et al.
NATURE (2008)
Patient-oncologist communication in advanced cancer: predictors of patient perception of prognosis
Tracy M. Robinson et al.
SUPPORTIVE CARE IN CANCER (2008)
Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group Study
William E. Winter et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Pretreatment CA-125 and risk of relapse in advanced ovarian cancer
M Markmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Communicating with realism and hope: Incurable cancer patients' views on the disclosure of prognosis
RG Hagerty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cancer patient preferences for communication of prognosis in the metastatic setting
RG Hagerty et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Identification of prognostic factors in advanced epithelial ovarian carcinoma
DS Chi et al.
GYNECOLOGIC ONCOLOGY (2001)
Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study
NA Christakis et al.
BRITISH MEDICAL JOURNAL (2000)
分享论文
